Company Information
Industry 制造业
Company Introduction 成都欧林生物科技股份有限公司是一家专注于人用疫苗研发、生产及销售的生物制药企业。公司成立于2009年,注册资本40526.5万元,于2021年6月8日,成功登陆上交所科创板(股票代码:688319)。公司自成立以来,一直致力于向国内外消费者提供安全有效和品质优异的人用疫苗产品,现累计获得中国发明专利62项,美国专利2项、欧洲专利1项,包括为提升人民群众生活品质而开发的,当前市场需求广阔的传统疫苗的升级换代产品;以及疾病控制和预防需求尚未满足或急需的,未来市场潜力巨大的创新疫苗产品。 本公司秉承“强化过程管理,致力持续改进,追求最高品质”的经营理念,以成为“国际知名、国内领先”的疫苗供应商为发展宗旨。在药品生产车间建设和管理方面,公司在符合我国2010版GMP基础上,参照欧美发达国家标准建设和管理,为公司产品进入国际市场打下坚实基础。在产品开发方面,公司研发体系搭建完善,同时拥有重庆原伦生物科技有限公司及成都新诺明生物科技有限公司两家子公司,合力实行“创新疫苗开发+传统疫苗升级换代”双轮驱动和“自主研发+联合研发”双翼齐飞的产品开发策略。公司目前上市疫苗产品3款,形成了“多产品储备、阶梯有序、重点突破”的产品管线。
Main Business 人用疫苗的研发、生产及销售
Legal Representative 樊绍文
Top Executives
董事长:樊绍文
副董事长:樊钒
董事:余云辉,樊绍文,胡成,陈爱民,樊钒
独立董事:何少平,李先纯 ,王乔
Top 5 Shareholder
Shareholder name Nature Holding Date
上海武山生物技术有限公司流通A股17.83%30/09/2024
樊钒限售股+流通A股7.53%30/09/2024
泰昌集团有限公司流通A股6.38%30/09/2024
樊绍文限售股+流通A股3.86%30/09/2024
招商银行股份有限公司-兴全合润混合型证券投资基金流通A股3.78%30/09/2024
Company Secretary 吴畏
Solicitors 上海市瑛明律师事务所
Auditors 中勤万信会计师事务所(特殊普通合伙)
Tel No 028-69361198
Fax No 028-69361100
Website www.olymvax.com
Email ir@olymvax.com
Company Address
Register: 四川省成都高新区天欣路99号
Office: 四川省成都高新区天欣路99号
Listing Date 08/06/2021
Shares Capital
Shares Capital: 405,933,600
Total A Share: 405,933,600
Listed A Share: 405,409,300
Non-tradable A Share: 524,300
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.043
DPS(RMB)* ¥ 0.038
NBV Per Share(RMB)* ¥ 2.258
Market Capitalization(RMB) 4.464B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.